Med-ePHV Project Keeping an Eye on Medicine

Medicines impact the lives of millions of people and strengthen their well-being, but there are risks involved in their use. Scientists agree that risk assessment during drug development should be carried out rigorously, but identifying safety concerns during clinical trials is complex. Pharmacovigilance is a field of science dedicated to the understanding and prevention of the adverse effects of medicines. The Med-ePHV (Learning and practicing pharmacovigilance in the Mediterranean countries) project, funded under the EU's Sixth Framework Programme (FP6) with EUR 804,420, has proposed an innovative approach to EU pharmacovigilance practice.

Health practitioners and patients are the first to recognise Adverse Drug Reactions (ADR) and to notify the appropriate authorities. But the process is complicated by inefficient delivery of notifications to both national and European agencies.

EU pharmaceutical regulators stress the importance of pharmacovigilance to the well-being of European citizens. Med-ePHV sought to design and implement a cooperative e-learning system that addresses the needs and profiles of Mediterranean-based health practitioners and patients, in particular those from Spain, France and Italy.

The project partners believed their innovative system 'would allow the parties involved to learn and practise ADRs notification at the peripheral edge of the pharmacovigilance systems'.

The team also aimed to develop pharmacovigilance e-learning courses and tutoring strategies that comply with EU legislation and can be adapted to the needs of national implementation schemes. They targeted the testing and validation of the e-learning modules in a representative sample of health practitioners and selected pharmaceutical industry representatives.

Finally, the researchers sought to design a cooperative environment as the central component of an 'application grid' that would be accessible to local health authorities and health practitioners. Partnership agreements would then be forged so that the e-learning modules could be commercially exploited.

Launched in September 2006, the grid-based computing platform included an online pilot for training on ADRs notification and reporting that complied with established international standards, and 'pharmacovigilance e-learning courses and tutoring schemes' that both supported knowledge-based ADRs specification and addressed correlation and standardisation issues.

Participating in the project were the small- and medium-sized enterprises (SMEs) Arisoft Editorial (Spain), PasteurMediavita (France) and Gruppo S LAB (Italy). The Spanish group specialises in internet portals targeting the promotion of specialised training programmes in various sectors such as health. PasteurMediavita offers specialised, health-related conventional and internet support training, and Gruppo supplies medical information products.

The SMEs worked together with research and technology development groups, including France's National Institute of Health and Medical Research and the University of Pavia in Italy, to make the project a success. The European Forum of Clinical Good Practice also took part by raising awareness of the project's results at the EU level.

For futher information, please visit:
http://www.medephv.net

Copyright ©European Communities, 2009
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...